[
  {
    "ts": "2026-02-05T13:00:00+00:00",
    "headline": "Cell and Gene Therapy in Numbers: $1.2B in Zolgensma Sales, $1.5B Yescarta Revenue, 46 FDA-Approved Therapies and $2B Strategic Deals",
    "summary": "This report provides an in-depth analysis of the Cell and Gene Therapy industry, highlighting key company revenues, regulatory approvals, and market trends. It has been compiled by Towards Healthcare, a sister firm of Precedence Research, offering valuable insights into the latest developments and financials in this rapidly advancing field.Ottawa, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cell and gene therapy (CGT) is rapidly advancing, with major players like Novartis, Gilead, and Bristol Myers Squibb",
    "url": "https://finance.yahoo.com/news/cell-gene-therapy-numbers-1-130000843.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "d5984552-e132-3083-92f2-3c08de3750a2",
      "content": {
        "id": "d5984552-e132-3083-92f2-3c08de3750a2",
        "contentType": "STORY",
        "title": "Cell and Gene Therapy in Numbers: $1.2B in Zolgensma Sales, $1.5B Yescarta Revenue, 46 FDA-Approved Therapies and $2B Strategic Deals",
        "description": "",
        "summary": "This report provides an in-depth analysis of the Cell and Gene Therapy industry, highlighting key company revenues, regulatory approvals, and market trends. It has been compiled by Towards Healthcare, a sister firm of Precedence Research, offering valuable insights into the latest developments and financials in this rapidly advancing field.Ottawa, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cell and gene therapy (CGT) is rapidly advancing, with major players like Novartis, Gilead, and Bristol Myers Squibb",
        "pubDate": "2026-02-05T13:00:00Z",
        "displayTime": "2026-02-05T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/47160fa420d06f24420d9a27698245a7",
          "originalWidth": 1667,
          "originalHeight": 1667,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2XVm_GDF06LCL8xJEgs9kg--~B/aD0xNjY3O3c9MTY2NzthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/47160fa420d06f24420d9a27698245a7.cf.webp",
              "width": 1667,
              "height": 1667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ciHBcKYhN1HkkZYm0oIo1A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/47160fa420d06f24420d9a27698245a7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/cell-gene-therapy-numbers-1-130000843.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cell-gene-therapy-numbers-1-130000843.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVS"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-05T14:15:06+00:00",
    "headline": "Ahead of Gilead (GILD) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics",
    "summary": "Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Gilead (GILD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.",
    "url": "https://finance.yahoo.com/news/ahead-gilead-gild-q4-earnings-141506652.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "22e5840f-9245-3b0b-a8a7-b2a019d859e7",
      "content": {
        "id": "22e5840f-9245-3b0b-a8a7-b2a019d859e7",
        "contentType": "STORY",
        "title": "Ahead of Gilead (GILD) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics",
        "description": "",
        "summary": "Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Gilead (GILD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.",
        "pubDate": "2026-02-05T14:15:06Z",
        "displayTime": "2026-02-05T14:15:06Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/d0d4ab152198da2f423d92da8a7d22ee",
          "originalWidth": 900,
          "originalHeight": 876,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/H7_MbG.UY.XzK7FHlqhSdQ--~B/aD04NzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d0d4ab152198da2f423d92da8a7d22ee.cf.webp",
              "width": 900,
              "height": 876,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9cdhr7KlQi2r1salrGcJQg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d0d4ab152198da2f423d92da8a7d22ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ahead-gilead-gild-q4-earnings-141506652.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ahead-gilead-gild-q4-earnings-141506652.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-05T14:15:00+00:00",
    "headline": "Should You Buy, Hold, or Sell GILD Stock Ahead of Q4 Earnings?",
    "summary": "GILD readies Q4 results as HIV drugs Biktarvy and Descovy drive growth, while Yeztugo uptake and cell therapy headwinds shape expectations.",
    "url": "https://finance.yahoo.com/news/buy-hold-sell-gild-stock-141500332.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "935934c3-cfac-3ca7-9314-a7c82fa95a37",
      "content": {
        "id": "935934c3-cfac-3ca7-9314-a7c82fa95a37",
        "contentType": "STORY",
        "title": "Should You Buy, Hold, or Sell GILD Stock Ahead of Q4 Earnings?",
        "description": "",
        "summary": "GILD readies Q4 results as HIV drugs Biktarvy and Descovy drive growth, while Yeztugo uptake and cell therapy headwinds shape expectations.",
        "pubDate": "2026-02-05T14:15:00Z",
        "displayTime": "2026-02-05T14:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tEjPL1xniTl4Yv5crLKiVw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3wQ5IrbXljgjZ16xqKRVcQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/buy-hold-sell-gild-stock-141500332.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/buy-hold-sell-gild-stock-141500332.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "GLAXF"
            },
            {
              "symbol": "GSK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-05T15:00:06+00:00",
    "headline": "Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?",
    "summary": "Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finance.yahoo.com/news/agios-pharmaceuticals-agio-expected-beat-150006355.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "323fdb94-0941-3276-9e0e-689c9620e476",
      "content": {
        "id": "323fdb94-0941-3276-9e0e-689c9620e476",
        "contentType": "STORY",
        "title": "Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?",
        "description": "",
        "summary": "Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
        "pubDate": "2026-02-05T15:00:06Z",
        "displayTime": "2026-02-05T15:00:06Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/39dfb058875b6e691de9136bc97a47b4",
          "originalWidth": 900,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/96m3P4v2KypZ_.2vXHQRKA--~B/aD05MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/39dfb058875b6e691de9136bc97a47b4.cf.webp",
              "width": 900,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TvxSS8VO1p90iNVKrfS9eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/39dfb058875b6e691de9136bc97a47b4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/agios-pharmaceuticals-agio-expected-beat-150006355.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/agios-pharmaceuticals-agio-expected-beat-150006355.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AGIO"
            },
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]